CJC-1295 vs Ipamorelin: evidence, status and structure
A side-by-side look at CJC-1295 and Ipamorelin, using the data on each VALREXA profile. Neither comparison is a recommendation.
Key differences
- Both sit at the same evidence level: Early human.
- Both have the same U.S. status category: Not FDA-approved.
- CJC-1295 is about 5.1× heavier than Ipamorelin (~3,647.2 vs ~711.9 Da).
| CJC-1295 | Ipamorelin | |
| Research class | Endocrine & Growth | Endocrine & Growth |
| Human evidence | Early human | Early human |
| U.S. status | Not FDA-approved | Not FDA-approved |
| 2026 compounding decision | — | — |
| Amino acids | 29 (peptide chain) | 5 |
| Molecular weight | ~3,647.2 Da | ~711.9 Da |
| Formula | Varies by form | C₃₈H₄₉N₉O₅ |
| Sequence | — | — |
| Research period | 2000s | 1990s |
| Safety summary | Not FDA-approved for therapeutic use. | Not FDA-approved for therapeutic use. |
How they differ
These act on two different receptors in the growth hormone system. CJC-1295 is a modified analogue of growth hormone-releasing hormone (GHRH) that acts on the GHRH receptor. Ipamorelin is a small growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a). Neither is FDA-approved, and human evidence for both is limited to early studies.
What each one is
CJC-1295: Synthetic growth hormone-releasing hormone analogue; DAC and non-DAC variants are chemically distinct. Molecular weight, sequence, research history, human evidence and regulatory status.
Ipamorelin: Synthetic pentapeptide studied as a ghrelin receptor agonist / growth hormone secretagogue. Molecular weight, sequence, research history, human evidence and regulatory status.
Educational reference only. Nothing here is medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error.